Table 1.
Summary of nanoconjugates: their abbreviations and physicochemical characterization.
| Imaging and treatment agents | Hydrodynamic diameter (nm)a |
Zeta potential (mV)b |
|---|---|---|
| poly(↕-L-malic acid) (PMLA) | 6.6 (±0.1) | −22.9 (±1.7) |
| P/MEA(4%)/Gd-DOTA(10–12%)c (Preconjugate-1) | 8.8 (±0.7) | −16.8 (±1.8) |
| P/cetuximab(0.12%)/MsTfR-mAb(0.12%)/Alexa-680(1%)/Gd-DOTA(10–12%) (P/Gd-DOTA/cetuximab/MsTfR-mAb/Alexa-680) | 16.0 (±1.5) | −8.7 (±1.2) |
| P/trastuzumab(0.12%)/MsTfR-mAb(0.12%)/Alexa-680 (1%)/Gd-DOTA(10–12%) (P/Gd-DOTA/trastuzumab/MsTfR-mAb/Alexa-680) | 16.3 (±1.6) | −6.9 (±1.1) |
| P/mPEG(5%)/LOEt(40%)/MEA(4–6%) (Preconjugate-2) | 8.1 (± 0.5) | −8.45 (±1.2) |
| P/mPEG(5%)/LOEt(40%)/HuTfR-mAb(0.2%)/ MsTfRmAb(0.2%)/EGFR-AON(2–4%) (P/Hu/MsTfR-mAb/EGFR-AON) | 15.7 (± 2.0) | −2.61 (±0.8) |
| P/mPEG(5%)/LOEt(40%)/trastuzumab(0.2%)/MsTfR (0.2%)/HER2 AON(3–4%) (P/trastuzumab/MsTfR-mAb/HER2-AON) | 15.7 (± 2.0) | −4.09 (±.8) |
a
Hydrodynamic diameter by number distribution at 25°C measured in PBS at a concentration of 2 mg/ml, calculated from DLS data by Malvern Zetasizer software (Malvern Instruments, Malvern, UK), which assumes spherical shapes of particles.
b
zeta potential at 25°C in aqueous solution of 10 mM NaCl at 150 mV.
c
composition of nanoconjugates; percentage refers to total number (100%) of pendant carboxyl groups in unsubstituted PMLA.
License Number 3691200832253, License Date Aug 17, 2015
Licensed content publisher American Chemical Society